Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 7, 2011, Pages 4605-4609

  Chang Lin, Joan En ^a   Burke, James A ^a   Peng, Qing ^b   Lin, Ton ^a   Orilla, Werhner C ^a   Ghosn, Corine R ^a   Zhang, Kai Ming ^a   Kuppermann, Baruch D ^b   Robinson, Michael R ^a   Whitcup, Scott M ^a   Welty, Devin F ^a  

^a ALLERGAN INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DETERMINATION; DRUG IMPLANT; IN VIVO STUDY; INTRAOCULAR PRESSURE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; RETINA; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VITRECTOMY; VITREOUS BODY; ANIMAL; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DISEASE MODEL; DRUG EFFECT; EYE DISEASE; FOLLOW UP; METABOLIC CLEARANCE RATE; METABOLISM; POSTERIOR EYE SEGMENT;

ANIMALS; DELAYED-ACTION PREPARATIONS; DEXAMETHASONE; DISEASE MODELS, ANIMAL; DRUG IMPLANTS; EYE DISEASES; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; MALE; METABOLIC CLEARANCE RATE; POSTERIOR EYE SEGMENT; RABBITS; VITRECTOMY; VITREOUS BODY;

EID: 80052366693     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6387     Document Type: Article

References (39)

1. Laidlaw DA. Vitrectomy for diabetic macular oedema. Eye. 2008; 22(10):1337-1341.
2. Androudi S, Ahmed M, Fiore T, Brazitikos P, Foster CS. Combined pars plana vitrectomy and phacoemulsification to restore visual acuity in patients with chronic uveitis. J Cataract Refract Surg. 2005;31(3):472-478.
3. Parodi MB, Lanzetta P, Guarnaccia G, Friberg T. Surgical treatments of central retinal vein occlusion. Semin Ophthalmol. 2003; 18(3):142-146.
4. Arrigg PG, Cavallerano J. The role of vitrectomy for diabetic retinopathy. J Am Optom Assoc. 1998;69(11):733-740.
5. Lee SS, Ghosn C, Yu Z, et al. Vitreous VEGF clearance is increased after vitrectomy. Invest Ophthalmol Vis Sci. 2010;51(4):2135-2138.
6. Chin HS, Park TS, Moon YS, Oh JH. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina. 2005;25(5):556-560.
7. Schindler RH, Chandler D, Thresher R, Machemer R. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol. 1982; 93(4):415-417.
8. Doft BH, Weiskopf J, Nilsson-Ehle I, Wingard LB Jr. Amphotericin clearance in vitrectomized versus nonvitrectomized eyes. Ophthalmology. 1985;92(11):1601-1605.
9. Jarus G, Blumenkranz M, Hernandez E, Sossi N. Clearance of intravitreal fluorouracil: normal and aphakic vitrectomized eyes. Ophthalmology. 1985;92(1):91-96.
10. Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol. 2008; 126(9):1191-1201.
11. Enyedi LB, Pearson PA, Ashton P, Jaffe GJ. An intravitreal device providing sustained release of cyclosporine and dexamethasone. Curr Eye Res. 1996;15(5):549-557.
12. Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006;113(6):1020-1027.
13. Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007;125(3):309-317.
14. Morita Y, Ohtori A, Kimura M, Tojo K. Intravitreous delivery of dexamethasone sodium m-sulfobenzoate from poly(DL-lactic acid) implants. Biol Pharm Bull. 1998;21(2):188-190.
15. Silva-Cunha A, Fialho SL, Naud MC, Behar-Cohen F. Poly-epsiloncaprolactone intravitreous devices: an in vivo study. Invest Ophthalmol Vis Sci. 2009;50(5):2312-2318.
16. Xu J, Wang Y, Li Y, et al. Inhibitory efficacy of intravitreal dexamethasone acetate-loaded PLGA nanoparticles on choroidal neovascularization in a laser-induced rat model. J Ocul Pharmacol Ther. 2007;23(6):527-540.
17. Zhang L, Li Y, Zhang C, Wang Y, Song C. Pharmacokinetics and tolerance study of intravitreal injection of dexamethasone-loaded nanoparticles in rabbits. Int J Nanomedicine. 2009;4:175-183.
18. Antoszyk AN, Tuomi L, Chung CY, Singh A. Ranibizumab combined with verteporfin photodynamic therapy in neovascular agerelated macular degeneration (FOCUS): year 2 results. Am J Ophthalmol. 2008;145(5):862-874.
19. Chakravarthy U, Adamis AP, Cunningham ET Jr, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology. 2006;113(9):1508 e1501-e1525.
20. Kook D, Wolf A, Kreutzer T, et al. Long-term effect of intravitreal bevacizumab (Avastin) in patients with chronic diffuse diabetic macular edema. Retina. 2008;28(8):1053-1060.
21. Singerman LJ, Masonson H, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol. 2008;92(12):1606-1611.
22. Yeh PT, Yang CM, Lin YC, Chen MS, Yang CH. Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy. Retina. 2009;29(6):768-774.
23. Ozurdex [package insert]. Irvine, CA: Allergan, Inc.; 2010.
24. Chang-Lin E, Attar M, Acheampong A, et al. Pharmacokinetics and pharmacodynamics of the sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52(1):80-86.
25. Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6):1134-1146. e3.
26. Haller JA, Dugel P, Weinberg DV, Chou C, Whitcup SM. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina. 2009;29(1):46-51.
27. Williams GA, Haller JA, Kuppermann BD, et al. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol. 2009;147(6):1048-1054, 1054. e1-2.
28. Fialho SL, Rego MB, Siqueira RC, et al. Safety and pharmacokinetics of an intravitreal biodegradable implant of dexamethasone acetate in rabbit eyes. Curr Eye Res. 2006;31(6):525-534.
29. Kwak HW, D'Amico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol. 1992;110(2):259-266.
30. Weijtens O, Feron EJ, Schoemaker RC, et al. High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. Am J Ophthalmol. 1999;128(2):192-197.
31. Rorabacher D. Statistical treatment for rejection of deviant values: critical values of Dixon's "Q" parameter and related subrange ratios at the 95% confidence level. Anal Chem. 1991;63:139-146.
32. Gisladottir S, Loftsson T, Stefansson E. Diffusion characteristics of vitreous humour and saline solution follow the Stokes Einstein equation. Graefes Arch Clin Exp Ophthalmol. 2009;247(12): 1677-1684.
33. Friedrich S, Cheng YL, Saville B. Drug distribution in the vitreous humor of the human eye: the effects of intravitreal injection position and volume. Curr Eye Res. 1997;16(7):663-669.
34. Chastain J. General considerations in ocular drug delivery. In: Mitra A, ed. Ophthalmic Drug Delivery Systems. New York: Marcel Dekker, Inc; 2003:59-107.
35. Yasukawa T, Ogura Y, Tabata Y, Kimura H, Wiedemann P, Honda Y. Drug delivery systems for vitreoretinal diseases. Prog Retin Eye Res. 2004;23(3):253-281.
36. Maurice D. Review: practical issues in intravitreal drug delivery. J Ocul Pharmacol Ther. 2001;17(4):393-401.
37. Graham RO, Peyman GA. Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis. Arch Ophthalmol. 1974;92(2):149-154.
38. Gan IM, Ugahary LC, van Dissel JT, van Meurs JC. Effect of intravitreal dexamethasone on vitreous vancomycin concentrations in patients with suspected postoperative bacterial endophthalmitis. Graefes Arch Clin Exp Ophthalmol. 2005;243(11):1186-1189.
39. Boyer DS, Faber D, Gupta S, et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. In Press.